Drug General Information
Drug ID	D02INX
Former ID	DNCL003794
Drug Name	TD-1211
Drug Type	Small molecular drug
Indication	Opioid-induced constipation [ICD9: 564; ICD10:K59.0]		Phase 2	[523559]
Company	Theravance
Structure		Download 2D MOL 3D MOL
Formula	C26H39N3O4
PubChem Compound ID	67156338
Target and Pathway
Target(s)	Mu-type opioid receptor	Target Info	Modulator	[532292]
KEGG Pathway	Neuroactive ligand-receptor interaction
	Estrogen signaling pathway
	Morphine addiction
NetPath Pathway	TCR Signaling Pathway
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
	Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
	Enkephalin release
Pathway Interaction Database	IL4-mediated signaling events
Reactome	Peptide ligand-binding receptors
	G alpha (i) signalling events
WikiPathways	TCR Signaling Pathway
	GPCRs, Class A Rhodopsin-like
	Peptide GPCRs
	Opioid Signalling
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 523559	ClinicalTrials.gov (NCT01401985) A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC). U.S. National Institutes of Health.
Ref 532292	The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386(6):479-91.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.